27 C
April 14, 2024
The Hona News

Atezolizumab addition to chemotherapy after surgery does not improve survival for triple negative breast cancer: Study

Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their post-surgery chemotherapy treatment, according to the results of a large phase 3 clinical trial presented at the 14th European Breast Cancer Conference.

Source link

Related posts

Quitting smoking at any age brings big health benefits, fast: Study


Study explores accuracy of computerized ADHD test


Incisionless device could revolutionize treatment for diabetes, liver disease and severe obesity


Leave a Comment